xinbang phar.(SZ:002390) Sou Hu Cai Jing·2025-04-16 13:25Core Viewpoint - Xinfang Pharmaceutical (SZ002390) reported a decline in both revenue and net profit for the year 2024, indicating financial challenges for the company. Financial Performance - In 2024, Xinfang Pharmaceutical's operating revenue was 6.03 billion yuan, a decrease of 6.63% compared to 2023, which was 6.46 billion yuan [2] - The net profit attributable to shareholders was 101 million yuan, down 64.7% from 287 million yuan in 2023 [2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 165 million yuan, a decrease of 38.29% from 268 million yuan in 2023 [2] - The net cash flow from operating activities was 635 million yuan, down 19.69% from 791 million yuan in 2023 [2] - Basic and diluted earnings per share were both 0.05 yuan, a decline of 66.67% from 0.15 yuan in 2023 [2] - The weighted average return on net assets was 1.50%, down 2.69 percentage points from 4.19% in 2023 [2] - Total assets at the end of 2024 were approximately 9.03 billion yuan, a decrease of 2.34% from 9.24 billion yuan at the end of 2023 [2] - Net assets attributable to shareholders were approximately 6.71 billion yuan, down 2.08% from 6.85 billion yuan at the end of 2023 [2] - The net profit for 2024 marked the lowest level in six years, with figures from 2019 to 2024 being 236 million yuan, 174 million yuan, 273 million yuan, 224 million yuan, 287 million yuan, and 101 million yuan respectively [2] Legal Issues - Xinfang Pharmaceutical's subsidiary, Guizhou Kekai Pharmaceutical Co., Ltd., is under investigation for alleged unit bribery, involving its actual controller An Huailue [3] - The company announced that it received a notification regarding the court's acceptance of the bribery case, but it does not expect significant adverse effects on its profits for the current and future periods [3]